BACKGROUND: Treatment guidelines for colon cancer recommend colectomy with lymphadenectomy of at least 12 lymph nodes for patients with stage I to stage III disease as surgery adherence (SA) and adjuvant chemotherapy for individuals with stage III disease. Herein, the authors evaluated adherence to these guidelines among older patients in Texas with colon cancer and the associated survival outcomes. METHODS: Using Texas Cancer Registry data linked with Medicare data, the authors included patients with AJCC stage II and III colon cancer who were aged 66 years and diagnosed between 2001 and 2011. SA and adjuvant chemotherapy adherence rates to treatment guidelines were estimated. The chi-square test, general linear regression, survival probability, and Cox regression were used to identify factors associated with adherence and survival. RESULTS: The rate of SA increased from 47.2% to 84% among 6029 patients with stage II or stage III disease from 2001 to 2011, and the rate of adjuvant chemotherapy increased from 48.9% to 53.1% for patients with stage III disease during the same time period. SA was associated with marital status, tumor size, surgeon specialty, and year of diagnosis. Patient age, sex, marital status, Medicare state buy-in status, comorbidity status, and year of diagnosis were found to be associated with adjuvant chemotherapy. The 5-year survival probability for patients receiving guidelineconcordant treatment was the highest at 87% for patients with stage II disease and was 73% for those with stage III disease. After adjusting for demographic and tumor characteristics, improved cancer cause-specific survival was associated with the receipt of stage-specific, guideline-concordant treatment for patients with stage II or stage III disease. CONCLUSIONS: The adherence to guideline-concordant treatment among older patients with colon cancer residing in Texas improved over time, and was associated with better survival outcomes. Future studies should be focused on identifying interventions to improve guideline-concordant treatment adherence. Cancer 2018;124:679-87.
INTRODUCTION
Patients with stage II or stage III colon cancer are reported to have better 5-year survival if they receive guidelineconcordant treatment. 1 The National Comprehensive Cancer Network (NCCN) surgery guidelines for patients with stages I to III colon cancer include colectomy with lymphadenectomy of at least 12 nearby lymph nodes, which we denote as surgery adherence (SA). 2 For patients with stage III colon cancer, the NCCN recommends using the combination of 5-fluorouracil and leucovorin or capecitabine. The addition of oxaliplatin to the combination of 5-fluorouracil and leucovorin in patients aged 70 years is uncertain because to our knowledge it has not shown a survival benefit. 2 Because patients treated according to guideline recommendations have better survival outcomes, 1, [3] [4] [5] it is important to estimate the rate of guideline-concordant colon cancer care to monitor the quality of cancer treatment.
Each year, approximately 9000 residents of Texas are diagnosed with colorectal cancer; of these individuals, approximately 60% are aged 65 years. 6 The 5-year survival rate for patients with regional stage disease (which includes stage II and stage III disease) was reported to be 68.2% and the cost of colorectal cancer care was approximately $3.6 billion in Texas in 2007. 6 To reduce the burden of colon cancer and provide effective cancer care to patients in the state, we evaluated the trends in adherence to evidence-based guidelines for patients with stage II and III colon cancer who were diagnosed between 2001 and 2011. We hypothesized that the adherence increased over the years analyzed, and was associated with the increased survival of patients with colon cancer.
MATERIALS AND METHODS
We used Texas Cancer Registry data linked with Medicare for the current study. The patients with cancer in Texas were linked with the Medicare data by matching the patient's social security number, name, sex, and date of birth. 7 We identified patients with colon cancer who were diagnosed between 2001 and 2011 using International Classification of Diseases for Oncology, Third Edition (ICD-O-3)/World Health Organization 2008 Site Recode B recodes 21041 to 21049. Because American Joint Committee on Cancer (AJCC) staging was not recorded in the Texas Cancer Registry before 2006, we selected patients with regional stage disease with tumor direct extension without regional lymph node invasion (AJCC stage II), and those with regional lymph node involvement (AJCC stage III). Patients were aged 66 years with Medicare Part A and B coverage and were not covered by a health maintenance organization for 1 year before and 1 year after diagnosis or until death if patients died within 12 months of their diagnosis. The index month for the cohort selection was the month of the patient's cancer diagnosis. Patients underwent a colectomy within 6 months since their index month and survived at least 6 months after their cancer diagnosis. Details regarding the cohort selection are shown in Supporting Information Table 1. We included patient-level covariates such as demographics, socioeconomic status, residence area, tumor characteristics, receipt of surgery and chemotherapy, surgeon specialty, and comorbidity status at the time of diagnosis. The Charlson Comorbidity Index was generated using Medicare claims. 8, 9 We defined surgery as conventional colectomy or laparoscopy-assisted colectomy by using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure or Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) codes. Receipt of chemotherapy was defined based on whether the patient had their first claim for 5-fluorouracil, oxaliplatin, capecitabine, or leucovorin after undergoing colectomy and within 4 months after a diagnosis of colon cancer. Surgeon specialty was defined using the Medicare Specialty Codes in the surgery claims from physician files. The codes for defining surgery and chemotherapy are shown in Supporting Information Table 2. SA was defined as a patient receiving colectomy with lymphadenectomy of at least 12 lymph nodes. Adjuvant chemotherapy adherence for patients with stage III disease was defined as initiating adjuvant chemotherapy within 4 months of diagnosis after colectomy in patients aged 80 years according to the treatment guidelines published by the NCCN, the National Quality Forum, and the Quality Oncology Practice Initiative. 10 We evaluated the survival outcomes for patients based on stage-specific treatment. Patients were divided into 4 treatment groups according to their SA and adjuvant chemotherapy: 1) colectomy with < 12 lymph nodes removed with no chemotherapy (S); 2) SA with no chemotherapy (SA); 3) S followed by chemotherapy (S 1 adjuvant chemotherapy); and 4) SA followed by chemotherapy (SA 1 adjuvant chemotherapy). We defined stage-specific adherence to treatment guidelines as SA for stage II disease and SA 1 adjuvant chemotherapy for stage III disease. We estimated the 5-year colon cancer-specific survival (CSS). The survival time was calculated from the month of diagnosis until the month of death or the end of the study. If a patient was alive or had died of causes other than colon cancer at the time of last follow-up, the patient was censored at one of the following time points (whichever had occurred first): 1) date of death; 2) 5 years if the patient survived >5 years; or 3) December 31, 2012 (the end date of our available Medicare claims) if the patient was followed for <5 years.
Statistical Analysis
Means, medians, and frequencies were used to describe continuous and categorical variables. We used the chisquare test to compare the distribution of characteristics between the adherent and nonadherent patients for nominal variables and the Cochran-Armitage test for trend for ordinal categorical variables. Because the adherence rate was found to be >10%, general linear regression analysis was used to compute risk ratios with 95% confidence intervals (95% CIs) to evaluate the association of these factors with adherence status. 11 We estimated the stage-specific adherence rate and computed the 5-year CSS using the Kaplan-Meier method and conducted pairwise log-rank tests to compare survival rates by treatment groups. In Cox regression analysis evaluating the association between treatment adherence and patient survival, propensity score (PS) adjustment was used to control the differences in the patients' baseline prognosis factors of receiving a specific cancer treatment. We first computed Original Article the PS for each patient who received a specific treatment using a multinomial logistic regression model, and we then calculated the inverse probability of treatment weights (IPTW) using the PS. Finally, we used a forward stepwise Cox regression model adjusted for other covariates and the IPTW to obtain the hazard ratio (HR) and its 95% CI for the CSS for the each of the 3 nonadherence groups. The inclusion and exclusion criteria with a P value .1 were used to select variables in the final Cox model. All statistical tests were 2-sided at a significance level of .05 and were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). The current study received exemption from The University of Texas MD Anderson Cancer Center institutional review board.
RESULTS
We identified 2161 patients with stage II and 3868 patients with stage III colon cancer in Texas who underwent colectomy within 6 months of diagnosis; patient characteristics are shown in Table 1 . Approximately 64.4% of these 6029 patients with stage II or stage III disease received SA. The age distribution for the patients receiving SA and those not receiving SA were similar, with a median age of 76 years for both groups. The median number of lymph nodes examined was 18 for the SA group and 8 for the non-SA group. From 2001 to 2011, the SA rate steadily increased from 47.2% to 84.0%. Patients who were married, those with stage III disease, those with a large tumor size, or those whose surgery was performed by a colorectal specialist surgeon were more likely to have SA. The adjuvant chemotherapy rate was 50.3% among the 2737 patients with stage III disease who were aged 80 years. Over the 11-year period, the adjuvant chemotherapy rate increased from 48.9% in 2001 to 56.2% in 2005, and then slightly decreased to 53.1% in 2011. There was no significant increasing trend for adjuvant chemotherapy observed during the years examined. Factors associated with nonadherence to chemotherapy guidelines included age >75 years, male sex, and having a Charlson Comorbidity Index >1. Patients' marital status and year of diagnosis were found to be significantly associated with SA and adjuvant chemotherapy. Patients who had Medicare insurance covered by a state buy-in program were found to be 18% less likely to receive adjuvant chemotherapy compared with those not enrolled in a state buy-in program ( Table 2) .
Rates of SA and adjuvant chemotherapy based on patients' residence area by health service region are shown in Figures 1 and 2 . SA rates were highest in regions that included large cities such as Houston, Austin, and Dallas (eg, > 70% in the Houston area). In contrast, rates of adjuvant chemotherapy were not found to be high in any one particular region of Texas, with a range of 45% to 57%.
Approximately 51% of patients with stage II disease and 30% of patients with stage III disease received stagespecific, guideline-recommended treatment (Table 3) . For patients with stage II disease, SA was found to have the best 5-year survival rate of 87% compared with a survival rate of 77% for S and 84% for S 1 adjuvant chemotherapy (Table 3) (Fig. 3) . This survival benefit persisted after adjusting for other covariates and the IPTW in the Cox model. The HRs for S and S 1 adjuvant chemotherapy were 1.94 (95% CI, 1.50-2.50) and 1.75 (95% CI, 1.08-2.84), respectively, compared with patients receiving SA (Table 4 ). For patients with stage III disease, we found that chemotherapy was significantly associated with better survival compared with patients treated with surgery only. Patients receiving SA 1 adjuvant chemotherapy were found to have the highest survival probability (73%) among the 4 treatment groups. On Kaplan-Meier survival curves, the CSS for S 1 adjuvant chemotherapy was slightly better than that for SA (Fig. 4) . Although patients treated with S 1adjuvant chemotherapy were found to have a lower 5-year survival rate compared with patients treated with SA 1 adjuvant chemotherapy, these patients had a similar risk of cancer-related death in the Cox model adjusted for covariates and the IPTW (Table 3) (Fig. 4) . Other factors such as age, race, tumor size, and type of surgery also were found to be significantly associated with the risk of death for patients with stage II or stage III disease in the final Cox model (see Supporting Information Table 3 ). The proportional hazards assumptions for the final Cox model were satisfied for both patients with stage II and stage III disease.
DISCUSSION
The main finding of the current study was that adherence to surgical guidelines increased over time from 2001 to 2011, yet adherence to chemotherapy guidelines does not appear to have increased substantially. Patients who received stagespecific, guideline-recommended therapy were found to have better 5-year CSS compared with patients whose treatment differed from that of the guidelines.
To the best of our knowledge, the current study is the first to estimate the stage-specific treatment adherence rates for older patients with colon cancer according to the performance of colectomy with lymphadenectomy of at least 12 lymph nodes and receipt of chemotherapy. Earlier studies that evaluated stage-specific adherence rates based on the National Cancer Data Base or Medicare data linked with cancer registry data reported a 67% adherence rate for patients with stage II disease and an adherence rate ranging from 40% to 50% for patients with stage III disease 1, 12 ; these values are slightly higher than those of the current study. This may be due to those studies using colectomy as the criterion for SA without evaluating the number of lymph nodes removed. Using SA to evaluate the effect of surgery or chemotherapy is important because this criterion is significantly associated with better survival outcomes.
The current study identified potential modifiable factors that may improve the survival of patients with colon cancer. We found that patients whose surgery was performed by a colorectal specialist surgeon were 15% more likely to have SA compared with patients whose surgery was performed by a general surgeon. This result is consistent with the results of a study by Jeganathan et al, which reported a 14% increase in SA when treatment was performed by a colorectal specialist surgeon compared with a general surgeon. 13 Thus, hospitals or health care facilities should provide resources to improve general surgeons' knowledge and techniques to provide guidelinerecommended care to patients because in the study by Jeganathan et al, only 14% of patients with colon cancer underwent surgery with a colorectal surgeon. 13 We also found that low-income patients enrolled in Medicare state buy-in programs were 18% less likely to receive guidelineconcordant chemotherapy compared with non-buy-in enrollees. Low-income individuals with an income of 135% of the federal poverty level are eligible for the Medicare state buy-in program. This disparity in chemotherapy receipt for low-income patients may be due to buyin enrollees not being as physically or mentally fit as patients in non-buy-in programs to receive chemotherapy. It also may be due to a lack of oncologists that accept Medicare state buy-in patients because reimbursement for patients' cost sharing by the state buy-in program are low compared with that of non-buy-in patients. 14 The latter should encourage Texas health care policy makers to identify resources with which to improve chemotherapy reimbursement so that more oncologists would be willing to accept patients enrolled in Medicare state buy-in programs.
The current study has several strengths. To the best of our knowledge, it is the first study to date to describe trends in SA and adjuvant chemotherapy for patients with colon cancer who are aged 66 years in Texas. It was a large population-based cohort, which allowed us to perform various subgroup analyses to evaluate the survival benefit for patients who received adherent versus those who received nonadherent treatment. Although AJCC staging information was not available for patients diagnosed before 2006, we conducted a sensitivity analysis among patients who had AJCC staging and the concordance rates were found to be >90% for both stage II and stage III disease. However, there also are several limitations to the current study. Because this study focused on residents of Texas who were aged >65 years, the results may not be generalizable to patients in other states or those aged 65 years. We selected patients who survived for at least 6 months after their diagnosis, which excludes individuals who were too sick to receive treatment or patients who did not survive surgery or chemotherapy within 6 months of their administration; this may have led to an overestimation of the adherence rates because the current study cohort included relatively healthier patients. The current study did not assess potential confounding factors such as patient frailty and performance status, preferences, or physical and mental resilience, which may have affected their choice of treatment and survival.
Future work will focus on validating the stagespecific treatment adherence rates in older Medicare patients using a larger sample.
Conclusions
The results of the current study found that, in Texas from 2001 to 2011, approximately 64.4% of patients with 
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